EUVIMEDEUVIMED entdecken
Crossref

Real‐World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis

N Punchihewa iD, J K Nguyen, J M Armstrong iD, S Vogrin iD, C Dolianitis, C Baker, G Marshman, J Frew iD, J Wu, P Lowe, P Foley

Australasian Journal of Dermatology · 2026

DOI: 10.1111/ajd.70024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Australasian Journal of Dermatology, 2026. Verfasst von N Punchihewa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Skin Health Institute, Carlton, Victoria, Australia. Hauptthemen laut MEDLINE: Adalimumab, Psoriasis. Die Arbeit nennt 15 Literaturangaben. Gefördert von: F & E Bauer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although adalimumab has shown strong efficacy and safety in clinical trials, real‐world evidence in Australian patients with moderate‐to‐severe chronic plaque psoriasis is limited. This study assessed adalimumab efficacy and drug survival in routine clinical practice, comparing outcomes with the Phase 3 REVEAL trial and its open‐label extension.

Methods

Data were extracted from the Australasian Psoriasis Registry for adults meeting Pharmaceutical Benefits Scheme criteria to be prescribed adalimumab for chronic plaque psoriasis. Baseline demographics, Psoriasis Area and Severity Index (PASI) scores and treatment history between June 2006 and March 2022 were analysed. Drug survival was evaluated using Kaplan–Meier and Cox regression.

Results

A total of 306 patients were included; 59.8% had prior biologic exposure compared to 12.8% in REVEAL. The mean baseline PASI was 24.1 and at 3 months, 63.5% achieved PASI75 while 33.6% achieved PASI90. PASI90 responses remained stable through 3 years and exceeded REVEAL extension rates beyond 18 months. Median drug survival was 27.9 months; survival was 97.7%, 78.6%, 63.7% and 51.0% at 3, 9, 15 and 27 months, respectively. Male sex and achieving PASI ≤ 2 predicted longer drug survival.

Conclusions

In Australian real‐world practice, adalimumab demonstrated sustained effectiveness and drug survival in patients with chronic plaque psoriasis comparable to RCTs, despite higher baseline disease severity and greater prior biologic exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabPsoriasisHumansMaleFemaleMiddle AgedAdultAustraliaSeverity of Illness IndexTreatment OutcomeRegistriesAged

Stichwörter der Autor:innen

adalimumabdrug survivalpsoriasisreal‐world evidence

Substanzen

Adalimumab

Autor:innen und Institutionen

  • Skin Health Institute, Carlton, Victoria, Australia.
  • The University of Melbourne, Parkville, Victoria, Australia.
  • St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
  • Royal Melbourne Hospital, Parkville, Victoria, Australia.
  • Southern Adelaide Health Network, South Australia, Australia.
  • College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.

ORCID-Profile: N Punchihewa, J M Armstrong, S Vogrin, J Frew

Förderung

  • F & E Bauer Foundation

Zitieren

APA

Punchihewa, N., Nguyen, J. K., Armstrong, J. M., Vogrin, S., Dolianitis, C., Baker, C., Marshman, G., Frew, J., Wu, J., Lowe, P., & Foley, P. (2026). Real‐World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.70024

Vancouver

Punchihewa N, Nguyen JK, Armstrong JM, Vogrin S, Dolianitis C, Baker C, et al. Real‐World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis. Australasian Journal of Dermatology. 2026. doi:10.1111/ajd.70024

BibTeX
@article{Punchihewa2026,
  author = {Punchihewa, N and Nguyen, J K and Armstrong, J M and Vogrin, S and Dolianitis, C and Baker, C and Marshman, G and Frew, J and Wu, J and Lowe, P and Foley, P},
  title = {Real‐World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis},
  journal = {Australasian Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ajd.70024}
}
Kostenlos starten →